Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 4/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18764627 | 0.88 | DRD2 (0.42) | DRD2ALDH1A1GFERTDP1BRD4 | |
| SCHEMBL28230811 | 0.83 | ALDH1A1 (0.42) | DRD2ALDH1A1GFERTDP1BRD4 | |
| SCHEMBL21564315 | 0.82 | BRD4 (0.38) | ALDH1A1BRD4 | |
| SCHEMBL31487667 | 0.80 | NOTUM (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL15775751 | 0.77 | ALDH1A1 (0.43) | DRD2ALDH1A1GFERTDP1BRD4 | |
| SCHEMBL14737075 | 0.77 | PDE10A (0.50) | DRD2MALT1 | |
| SCHEMBL15199612 | 0.76 | ADRB3 (0.44) | ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL24841258 | 0.76 | ADRB3 (0.40) | ALDH1A1TDP1KMT2A | |
| SCHEMBL7464070 | 0.76 | ADRB3 (0.46) | TDP1MEN1KMT2A | |
| SCHEMBL24841256 | 0.75 | SSTR4 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2022-11-17 | — | — | US | disclosed |
| CN-114668761-A | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-108290878-B | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11066399-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-11066399-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-13 | — | — | US | disclosed |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-13 | — | — | US | disclosed |
| US-11001579-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-11 | — | — | US | disclosed |
| US-20190345151-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-11-14 | — | — | US | disclosed |
| US-20190345151-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-11-14 | — | — | US | disclosed |
| US-10364239-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-07-30 | — | — | US | disclosed |
| US-10364239-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-07-30 | — | — | US | disclosed |
| US-20180319783-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2018-11-08 | — | — | US | disclosed |
| US-20180297991-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2018-10-18 | — | — | US | disclosed |
| EP-3365339-A1 | NOVEL FERROPORTIN INHIBITORS | Vifor (International) AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| EP-3364967-A2 | FERROPORTIN INHIBITORS | Vifor (International) AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068089-A2 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017068090-A1 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345151-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | DRD2 2561/4885ALDH1A1 2812/4885GFER 766/4885 |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | DRD2 2561/4885ALDH1A1 2812/4885GFER 766/4885 |
| US-11066399-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | DRD2 2761/4885ALDH1A1 2395/4885GFER 725/4885 |
| US-20180297991-A1 | Novel Ferroportin Inhibitors | SLC40A1, HAMP, TFRC | DRD2 4645/4885ALDH1A1 1922/4885GFER 1483/4885 |
| US-11001579-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | DRD2 2761/4885ALDH1A1 2395/4885GFER 725/4885 |
| US-10364239-B2 | Ferroportin inhibitors | HAMP, SLC40A1, HMOX1 | DRD2 2717/4885ALDH1A1 1716/4885GFER 409/4885 |
| US-20180319783-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, FTH1 | DRD2 2847/4885ALDH1A1 1983/4885GFER 578/4885 |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | DRD2 2561/4885ALDH1A1 2812/4885GFER 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.